Victor Soriano Gomis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Victor Soriano Gomis has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Purificación Gonzalez Delgado
Servicio de Alergia, Hospital General Universitario de Alicante, Alicante, Spain
6 shared publications J L Fernández
4 shared publicationsE. Niveiro
3 shared publications- Andrés Aguilera
Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Universidad de Sevilla-CSIC-Universidad Pablo de Olavide, Seville, Spain
2 shared publications J Tor
2 shared publications- Javier Fernandez
Hospital General Universitario Alicante Alicante Spain
2 shared publications
Latest Publications
- Open Access
Molecular Diagnosis in Hymenoptera Allergy: Comparison of Euroline DPA-Dx and ImmunoCAP
The efficacy of Hymenoptera venom immunotherapy is contingent upon the accurate identification of the insect responsible for the allergic reaction. The techniques used to detect specific IgE suffer from difficulties due to the cross-reactivity between Hymenoptera venoms (false positives), diagnostic ability, and the limited availability of allergenic components (false negatives). In this study, we analyzed the discrepancies in the results obtained with Euroline® DPA-Dx and ImmunoCAP® in the diagnosis of allergic reactions due to Hymenoptera stings in 151 patients. The results (positive/negative) of ImmunoCAP® and Euroline® agreed in 77/151 (50.99%) cases; with 15/151 (9.93%) cases positive for the same insect, and 61/151 (40.4%) cases positive for multiple insects. When the results were used to decide which venom to use for immunotherapy, there was a statistically significant discrepancy for Polistes dominula (21.8% of cases with ImmunoCAP® compared to only 8.4% with Euroline®). The presence of Polistes venom phospholipase (Pol d 1) in Euroline® did not increase its ability to differentiate double sensitization to wasps. ImmunoCAP® and Euroline® exhibited comparable diagnostic performance in bee venom allergy. For vespid venom allergy—particularly involving Polistes species—ImmunoCAP® appeared to show a slight diagnostic advantage, although this finding should be interpreted with caution.
Open AccessMolecular Diagnosis in Hymenoptera Allergy: Comparison of Euroline DPA-Dx and ImmunoCAP
The efficacy of Hymenoptera venom immunotherapy is contingent upon the accurate identification of the insect responsible for the allergic reaction. The techniques used to detect specific IgE suffer from difficulties due to the cross-reactivity between Hymenoptera venoms (false positives), diagnostic ability, and the limited availability of allergenic components (false negatives). In this study, we analyzed the discrepancies in the results obtained with Euroline® DPA-Dx and ImmunoCAP® in the diagnosis of allergic reactions due to Hymenoptera stings in 151 patients. The results (positive/negative) of ImmunoCAP® and Euroline® agreed in 77/151 (50.99%) cases; with 15/151 (9.93%) cases positive for the same insect, and 61/151 (40.4%) cases positive for multiple insects. When the results were used to decide which venom to use for immunotherapy, there was a statistically significant discrepancy for Polistes dominula (21.8% of cases with ImmunoCAP® compared to only 8.4% with Euroline®). The presence of Polistes venom phospholipase (Pol d 1) in Euroline® did not increase its ability to differentiate double sensitization to wasps. ImmunoCAP® and Euroline® exhibited comparable diagnostic performance in bee venom allergy. For vespid venom allergy—particularly involving Polistes species—ImmunoCAP® appeared to show a slight diagnostic advantage, although this finding should be interpreted with caution.
- Open Access
- 13 May 2024
- Published by Elsevier in Atmospheric Environment
- Vol. 331
Influence of inputs from foreign source regions on daily profiles of Olea pollen at an urban site in the southeast of the Iberian Peninsula
- 13 May 2024
- Published by Elsevier in Atmospheric Environment
- Vol. 331
Open AccessInfluence of inputs from foreign source regions on daily profiles of Olea pollen at an urban site in the southeast of the Iberian Peninsula
- 1 February 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (2) , 1037-1038.e2
Epidemiology of Hymenoptera venom allergy in the Valencia Fire Brigade (Spain)
- 1 February 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (2) , 1037-1038.e2
Epidemiology of Hymenoptera venom allergy in the Valencia Fire Brigade (Spain)
- 1 February 2017
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 27 (1) , 19-31
Key Issues in Hymenoptera Venom Allergy: An Update
In this review, the Hymenoptera Allergy Committee of the SEAIC analyzes the most recent scientific literature addressing problems related to the diagnosis of hymenoptera allergy and to management of venom immunotherapy. Molecular diagnosis and molecular risk profiles are the key areas addressed. The appearance of new species of hymenoptera that are potentially allergenic in Spain and the associated diagnostic and therapeutic problems are also described. Finally, we analyze the issue of mast cell activation syndrome closely related to hymenoptera allergy, which has become a new diagnostic challenge for allergists given its high prevalence in patients with venom anaphylaxis.
- 1 February 2017
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 27 (1) , 19-31
Key Issues in Hymenoptera Venom Allergy: An Update
In this review, the Hymenoptera Allergy Committee of the SEAIC analyzes the most recent scientific literature addressing problems related to the diagnosis of hymenoptera allergy and to management of venom immunotherapy. Molecular diagnosis and molecular risk profiles are the key areas addressed. The appearance of new species of hymenoptera that are potentially allergenic in Spain and the associated diagnostic and therapeutic problems are also described. Finally, we analyze the issue of mast cell activation syndrome closely related to hymenoptera allergy, which has become a new diagnostic challenge for allergists given its high prevalence in patients with venom anaphylaxis.
- Open Access
- 1 February 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 139 (2) , AB32
Allergy to Betalactams Antibiotics at the End-of-Life Care
- 1 February 2017
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 139 (2) , AB32
Open AccessAllergy to Betalactams Antibiotics at the End-of-Life Care
- 1 June 2015
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 16 (8) , 825-839
Genetic Variants in Arachidonic Acid Pathway Genes Associated with NSAID-Exacerbated Respiratory Disease
Aim: NSAIDs are the most frequent cause of hypersensitivity drug reactions. We have examined the association between NSAID-exacerbated respiratory disease (NERD) and genetic variants in arachidonic acid metabolism genes. Patients & methods: We included 250 NERD patients, 260 NSAID-tolerant asthmatic (NTA) subjects and 315 healthy controls. Results: Significant associations with NERD were identified for: ALOX15 rs3892408 C/C homozygous genotype (NERD vs NTA; p = 0.0001, pc = 0.0011; NERD vs controls; p = 0.0001, pc = 0.0011), PTGS-1 rs5789 A/A homozygous genotype (NERD vs NTA; p = 0.0001, pc = 0.0011; NERD vs controls; p = 0.0001, pc = 0.0011), PTGS-1 rs10306135 A/A homozygous genotype (NERD vs NTA; p = 0.0009, pc = 0.0091; NERD vs controls; p = 0.0064, pc = 0.045). Differences in ALOX5 copy number variations were also found (NERD vs NTA; p = 0.010; NERD vs controls; p = 0.0001). Conclusion: These results improve our understanding of the underlying mechanisms of NERD and may help develop a predictive test ...
- 1 June 2015
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 16 (8) , 825-839
Genetic Variants in Arachidonic Acid Pathway Genes Associated with NSAID-Exacerbated Respiratory Disease
Aim: NSAIDs are the most frequent cause of hypersensitivity drug reactions. We have examined the association between NSAID-exacerbated respiratory disease (NERD) and genetic variants in arachidonic acid metabolism genes. Patients & methods: We included 250 NERD patients, 260 NSAID-tolerant asthmatic (NTA) subjects and 315 healthy controls. Results: Significant associations with NERD were identified for: ALOX15 rs3892408 C/C homozygous genotype (NERD vs NTA; p = 0.0001, pc = 0.0011; NERD vs controls; p = 0.0001, pc = 0.0011), PTGS-1 rs5789 A/A homozygous genotype (NERD vs NTA; p = 0.0001, pc = 0.0011; NERD vs controls; p = 0.0001, pc = 0.0011), PTGS-1 rs10306135 A/A homozygous genotype (NERD vs NTA; p = 0.0009, pc = 0.0091; NERD vs controls; p = 0.0064, pc = 0.045). Differences in ALOX5 copy number variations were also found (NERD vs NTA; p = 0.010; NERD vs controls; p = 0.0001). Conclusion: These results improve our understanding of the underlying mechanisms of NERD and may help develop a predictive test ...
- Open Access
- 1 June 2015
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 8, 14-16
From respiratory sensitization to food allergy: Anaphylactic reaction after ingestion of mushrooms (Agaricus bisporus)
- 1 June 2015
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 8, 14-16
Open AccessFrom respiratory sensitization to food allergy: Anaphylactic reaction after ingestion of mushrooms (Agaricus bisporus)
- 1 January 2012
- Vol. 22 (1) , 65-6
Glatiramer acetate anaphylaxis: detection of antibodies and basophil activation test.
- 1 January 2012
- Vol. 22 (1) , 65-6
Glatiramer acetate anaphylaxis: detection of antibodies and basophil activation test.
- 1 August 2008
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 36 (5) , 311-312
Allergy to iguana
- 1 August 2008
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 36 (5) , 311-312
Allergy to iguana
- 1 January 2008
- Vol. 18 (3) , 225-6
Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy.
- 1 January 2008
- Vol. 18 (3) , 225-6
Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy.